Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
Skotnicki A, Lissitchkov TJ, Mamonov V, Buevich E, Kuliczkowski K, Goranov S, Kłoczko J, Klukowska A, Stankovic S, Gercheva L, Chernova T, Hellmann A, Dmoszyńska A, Zawilska K, Veldman A, Joch C, Seifert W. Skotnicki A, et al. Among authors: zawilska k. Thromb Res. 2016 Jan;137:119-125. doi: 10.1016/j.thromres.2015.10.014. Epub 2015 Oct 13. Thromb Res. 2016. PMID: 26614676 Clinical Trial.
Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
Dmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O'Shaughnessy D, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Dmoszynska A, et al. Among authors: zawilska k. Haemophilia. 2011 May;17(3):456-62. doi: 10.1111/j.1365-2516.2010.02446.x. Epub 2011 Mar 4. Haemophilia. 2011. PMID: 21371184 Free PMC article.
Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A, Hellmann A, Baglin T, O'Shaugnessy D, Trelinski J, Kuliczkowski K, Kloczko J, Hay C, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Dmoszynska A, et al. Among authors: zawilska k. Haemophilia. 2011 Mar;17(2):185-90. doi: 10.1111/j.1365-2516.2010.02414.x. Epub 2010 Nov 11. Haemophilia. 2011. PMID: 21070496
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.
Blonski JZ, Robak T, Chojnowski K, Gora-Tybor J, Warzocha K, Ceglarek B, Seferynska I, Calbecka M, Kostyra A, Stella-Holowiecka B, Kloczko J, Dmoszynska A, Kowal M, Lewandowski K, Dwilewicz-Trojaczek J, Wiater E, Kuliczkowski K, Potoczek S, Hellmann A, Mital A, Skotnicki A, Nowak W, Sulek K, Zawilska K, Trelinski J. Blonski JZ, et al. Among authors: zawilska k. Eur J Haematol. 2013 Jul;91(1):1-9. doi: 10.1111/ejh.12112. Epub 2013 Apr 19. Eur J Haematol. 2013. PMID: 23521128 Clinical Trial.
Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J, Chojnowski K, Klukowska A, Łetowska M, Mital A, Podolak-Dawidziak M, Windyga J, Zawilska K; Working Group on Hemostasis of the Polish Society of Hematologists and Transfusiologists. Zdziarska J, et al. Among authors: zawilska k. Pol Arch Med Wewn. 2009 Jun;119(6):403-9. Pol Arch Med Wewn. 2009. PMID: 19694223 Free article. Review.
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A; Polish Adult Leukemia Group. Wierzbowska A, et al. Among authors: zawilska k. Eur J Haematol. 2008 Feb;80(2):115-26. doi: 10.1111/j.1600-0609.2007.00988.x. Epub 2007 Dec 11. Eur J Haematol. 2008. PMID: 18076637
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Robak T, et al. Among authors: zawilska k. Leuk Lymphoma. 2014 Mar;55(3):606-10. doi: 10.3109/10428194.2013.809073. Epub 2013 Nov 14. Leuk Lymphoma. 2014. PMID: 23721512 Clinical Trial.
148 results